Explore the Global Idiopathic Pulmonary Fibrosis Management Market — Key Trends, Regional Growth, Top Players, and 10-Year Forecast from 2026 to 2036

Future Market Insights

Idiopathic Pulmonary Fibrosis Management Market

Key Insight

Idiopathic pulmonary fibrosis management sales will expand through 2036, with nintedanib holding 39.6% of the drug class segment in 2026. The market was valued at USD 3.25 billion in 2025 and is expected to reach USD 3.9 billion by 2036, creating an incremental opportunity of USD 0.61 billion between 2026 and 2036.

April 28, 2026

Anurag Sharma

290 Pages

Cite this Report

Idiopathic Pulmonary Fibrosis Management Market

https://www.futuremarketinsights.com/reports/idiopathic-pulmonary-fibrosis-management-market

License

Starting at US$ 5000

Buy Now

Summary ToC Infographics Companies

Key Players

Biogen Inc
Blade Therapeutics
Boehringer Ingelheim
Bristol-Myers Squibb
FibroGen Inc
Galapagos NV
Genentech (Roche Holding AG)
Medicinova Inc
Novartis
Pliant Therapeutics
Samumed
Veracyte Inc

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Idiopathic Pulmonary Fibrosis Management Market

Key Players

Similar Industry Reports